GHRP-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide ghrelin receptor agonist that stimulates growth hormone release and produces significant appetite stimulation — the latter making it distinctive among GHRPs and clinically interesting for cachexia research. It is not approved for any medical indication and is sold as a research-use-only compound by third-party laboratories.

What is GHRP-6 and how does the dual GH/appetite mechanism work?

GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) that binds the ghrelin receptor (GHS-R1a) on both pituitary somatotrophs (producing GH release) and hypothalamic neurons in the arcuate nucleus (producing appetite stimulation). The dual effect distinguishes GHRP-6 from more selective GHRPs like ipamorelin (which avoids the appetite effect) and GHRP-2 (which has only mild appetite effects). Half-life is approximately 60 minutes.

Evidence level: human PK and Phase 1/2 (cachexia indications); no Phase 3 approval

What does the research show for GHRP-6?

GHRP-6 was the first orally-active GH-releasing hexapeptide and the earliest in the GHRP class to reach clinical research. Phase 1/2 trials have explored GHRP-6 for cancer cachexia, anorexia, and post-gastric-surgery weight recovery — the appetite-stimulation profile is therapeutically interesting in wasting conditions. No Phase 3 efficacy approval has been achieved. Human PK studies confirm reliable dose-dependent GH and IGF-1 elevation with substantial appetite increase.

Evidence level: phase 1/2 human (cachexia indications); no Phase 3 approval

How does GHRP-6 compare to ipamorelin and GHRP-2?

GHRP-6 is the appetite-stimulation GHRP — same ghrelin-receptor mechanism as ipamorelin and GHRP-2 but with substantially greater hypothalamic appetite-receptor engagement. The appetite effect is the differentiating feature.

What are the documented side effects of GHRP-6?

The most prominent GHRP-6 side effect is appetite stimulation, which is dose-related and pronounced. Beyond appetite, mild cortisol and prolactin elevation occurs, along with injection-site reactions and occasional transient flushing. The appetite effect is the primary clinical and research signal — buyers seeking GH-release effects without significant hunger generally choose ipamorelin or GHRP-2 instead.

Evidence level: phase 1/2 human safety; long-term unestablished

What is the regulatory status of GHRP-6?

GHRP-6 is not approved for any medical indication anywhere in the world as of August 2026. Phase 1/2 work in cachexia indications has not advanced to Phase 3 approval. It is sold strictly as a research-use-only compound by third-party laboratories. Regulatory context in are peptides legal regulatory status by country.

Why does GHRP-6 vendor verification matter?

GHRP-6 synthesis is mature and widely distributed in the research-grade market, but identity verification matters because related hexapeptide GHS compounds — GHRP-2, hexarelin — can be mislabeled. Independent HPLC purity testing and mass spectrometry identity confirmation (expected MW 873.0 Da) are the meaningful purity signals. Guidance in how-to-test-peptides hub.

How does Peptigrity verify GHRP-6 vendors?

Peptigrity collects independent third-party Certificates of Analysis for GHRP-6 from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate.

Frequently asked questions

Why does GHRP-6 cause hunger?

GHRP-6 binds the ghrelin receptor in the hypothalamic arcuate nucleus, which is the brain region that mediates the appetite-stimulating effects of endogenous ghrelin. More selective GHRPs like ipamorelin avoid this hypothalamic engagement and don't produce the same hunger effect. The appetite effect is a function of receptor binding profile, not a side effect that can be dose-titrated away.

Is GHRP-6 legal to purchase?

GHRP-6 is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.

What's the difference between GHRP-6 and ipamorelin?

Both are ghrelin-receptor agonists that stimulate GH release, but ipamorelin is much more selective — it produces minimal cortisol/prolactin effects and essentially no appetite stimulation. GHRP-6 produces substantial hunger. Buyers seeking GH-release effects without appetite stimulation typically prefer ipamorelin.

Does GHRP-6 show up on a drug test?

Yes. GHRP-6 and other GHRPs are on the WADA Prohibited List (Section S2 — Peptide Hormones). For drug-testing context, see do peptides show up on drug tests.

How can I verify a GHRP-6 vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation (expected MW 873.0 Da). Mass spec distinguishes GHRP-6 from related hexapeptide GHS compounds. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a GHRP-6 dose?

No. GHRP-6 is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. GHRP-6 is not approved by the FDA or any other regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.